Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Drug Pricing Reform: No More Medicare 'Gravy Train,' Azar Tells Pharma

Executive Summary

HHS secretary urges serious proposals from biopharma on enhancing price negotiation in Medicare Parts D and B, promising action from the Administration whether the industry cooperates or not.

You may also be interested in...



Highest-Cost Drugs Could Feel Biggest Pinch From Part B Step Therapy Policy

Biosimilars for Remicade and Neulasta could get boost, and off-label Avastin use for age-related macular degeneration could increase, challenging Eylea and Lucentis.

Pharma Q2 Results Preview: Celgene, Amgen, Allergan And AbbVie

With the FDA updating its stance on interchangeability, analysts will be pushing Amgen and AbbVie on how the policy changes will affect biosimilar competition. Celgene and Allergan will be under pressure for R&D updates; Allergan remains in the hot seat on its pipeline growth strategy from activist investors.

Pharma Q2 Results Preview: Celgene, Amgen, Allergan And AbbVie

With the FDA updating its stance on interchangeability, analysts will be pushing Amgen and AbbVie on how the policy changes will affect biosimilar competition. Celgene and Allergan will be under pressure for R&D updates; Allergan remains in the hot seat on its pipeline growth strategy from activist investors.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS123134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel